Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2000-05-18
2002-07-02
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C562S621000, C562S623000, C562S573000
Reexamination Certificate
active
06414029
ABSTRACT:
FIELD OF INVENTION
The present invention relates to vanadium complexes of monohydroxamates and to pharmaceutical compositions comprising them useful for the treatment of diabetes.
ABBREVIATIONS Asp(&bgr;)HXM, L-aspartic acid &bgr;-monohydroxamate; CytPTK, cytosolic protein-tyrosine kinase; Glu(&ggr;)HXM, L-glutamic acid &ggr;-monohydroxamate; HXM, monohydroxamate; InsRTK, insulin receptor tyrosine kinase; IRS-1, Insulin receptor substrate 1; PTK, protein tyrosine kinase; KRB, Krebs Ringer bicarbonate; NaVO
3
, sodium metavanadate; STZ, streptozocin; VOSO
4
, vanadyl sulphate; VOCl
2
, vanadyl chloride.
BACKGROUND OF THE INVENTION
Intensive studies have been carried out in the last two decades on the insulinomimetic effects of vanadium (reviewed in Shechter et al.,1995). In vitro, vanadium salts mimic most of the effects of insulin on the main target tissues of the hormone, and in vivo they induce normoglycemia, and improve glucose homeostasis in insulin-deficient and insulin-resistant diabetic rodents (reviewed in Brichard and Henquin, 1995). In the basic research frontier, data continues to accumulate showing that vanadium salts manifest their insulin-like metabolic effects through alternative pathways, not involving insulin-receptor tyrosine kinase activation, nor phosphorylation of insulin-receptor substrate 1 (IRS-1). The key players of his back-up system appear to involve inhibition of protein-phosphotyrosine phosphatases and activation of nonreceptor protein tyrosine kinases (reviewed in Brichard and Henquin, 1995).
Vanadium is an ultra trace element in mammals. The dietary intake varies between 10-60 &mgr;g day
−1
, and the intracellular concentration is approximately 20 nM (reviewed in Shechter et al., 1995 and Brichard and Henquin, 1995). The bulk of the intracellular vanadium is probably in the vanadyl (+4) form. Acute oral administration of vanadium compounds proved to be moderately toxic. Nevertheless, the profound anti-diabetic effects of oral vanadium therapy in insulin-deficient and insulin-resistant diabetic rodents (reviewed in Brichard and Henquin, 1995) encouraged the start of clinical studies. Small doses of vanadium (100-125 mg/person/day, over a period of 3 weeks) were allowed and, although 100 fold lower than those used in most animal studies, several beneficial effects were observed (Cohen et al., 1995).
Organically chelated vanadium (+4) complexes are about 5 fold more potent than free vanadium (+4) in facilitating the metabolic effects of insulin in vitro (Li et al., 1996) and in STZ-rats in vivo (Sakurai et al., 1995). The theoretical basis for that is still under study, and is likely the result of stabilizing the more potent insulin-like vanadium species.
Vanadium salts mimic the metabolic effects of insulin through alternative insulin-independent machinery components in vitro and can overcome states of insulin-resistance in diabetic rodents in vivo . As such vanadium therapy could make a useful, attractive and complementary approach to insulin therapy, provided that vanadium salts were less toxic or certain manipulation could be made to carry on vanadium therapy with no, or reduced quantities of, exogenous vanadium source.
Israel Patent No. 99666 and corresponding U.S. Pat. No. 5,338,759 of the same applicants describe vanadyl complexes of dihydroxamates of the formula:
R
2
R
3
C{CH
2
O(CH
2
)
m
CO[NHCHR(CH
2
)
q
CO]
n
NOHR
1
}
2
which are said to be useful for the treatment of diabetes, but were later found by the inventors to be unsuitable in vivo for normalizing blood glucose levels in model diabetic rats.
Hydroxamic acid derivatives were shown to be involved in the microbial transport of iron, and therefore suggested for treatment of conditions of iron deficiency. They are also inhibitors of urease activity and indicated for the treatment of hepatic coma. Much of their biological activities are related to their potency to chelate a variety of metals. In the majority of metal chelates formed by hydroxamic acids, coordination occurs by deprotonation of the OH group and subsequent (O,O) coordination with the carbonyl oxygen and deprotonated OH.
Amino acid monohydroxamates are simple, nontoxic derivatives of amino acids. D-Aspartic acid &bgr;-hydroxamate (D-Asp(&bgr;)HXM) was shown to have antitumoral activity on murine leukemia L5178Y, both in vitro and in vivo, and is active against Friend leukemia cells in vitro (Tournaire et al., 1994). L-Glutamic acid (&ggr;)-monohydroxamate (Glu(&ggr;)HXM) is cytotoxic against leukemia L1210 cells in vitro, and against leukemia L1210 and melanoma B16 cells in vivo (Vila et al., 1990).
SUMMARY OF THE INVENTION
It has now been found in accordance with the present invention that certain amino acid monohydroxamates (HXM), in particular the L-forms of glutamic acid &ggr;-monohydroxamate (Glu(&ggr;)HXM) and aspartic acid &bgr;-monohydroxamate (Asp(&bgr;)HXM), interact with vanadium (+4) and vanadium (+5). At a 1:1 or 2:1 HXM: vanadium molar stoichiometry, they largely potentiate the insulinominetic potencies of vanadium (+4) and (+5) in vitro, and normalize the blood glucose level of streptozocin-treated rats in vivo.
The present invention relates to novel vanadium complexes of monohydroxamates of the formula (I):
R—CO—NHOH.X (I)
wherein
R is a residue selected from:
(i) H
2
N—CH (COY)—(CH
2
)
n
—
(ii) H
2
N—CH (COOH)—CH
2
—S—CH
2
—; and
(iii) pyridyl, piperidyl or tetrahydroisoquinolinyl;
wherein n is 1, 2 or 3, and Y is OH or NH
2
; and X is a vanadium compound selected from a vanadyl (VO
2+
), metavanadate (VO
3
−
) or vanadate (VO
4
3−
) salt.
According to the present invention, in the monohydroxamates of (i) above, n is preferably 1 or 2, namely the &bgr;- and &ggr;-monohydroxamates of L-aspartic acid and L-glutanic acid, respectively. In a most preferred embodiment, the amino acid monohydroxamate is Glu(&ggr;)HXM, that was found to be more effective in the manifestation of the metabolic effects of insulin in rat adipocytes as compared to various &agr;-amino acid monohydroxamates.
Interestingly enough, among all known vanadium chelators disclosed in the literature such as acetylacetonate, bispicolinato and the dihydroxamate RL-252 described in the above-mentioned U.S. Pat. No. 5,338,759, amino acid monohydroxamates are unique in their capacity to produce insulin effects, in vitro, in the absence of externally added vanadium, indicating that amino acid monohydroxamates might be capable of converting the minute quantity of intracellularly located vanadium (+4, ~20 nM) into an insulinomimetically-active species. Further studies in vitro revealed that Glu(&ggr;)HXM facilitates all the physiologically relevant bioeffects of insulin. These include activation of hexose uptake and inhibition of isoproterenol mediated lipolysis. Quite importantly, activation by Glu(&ggr;)HXM is additive to maximal effect produced by a saturated concentration of insulin.
Among the monohydroxamates of (iii) above, preferred are the 3-pyridyl radical, namely the nicotinic acid hydroxamate, the 2- or 3-piperidyl radical and the 3-tetrahydroisoquinolinyl radical.
The monohydroxamates used in the present invention are soluble in water in contrast to the dihydroxamates of the above mentioned U.S. Pat. No. 5,338,759, that are water insoluble. Thus the vanadium complexes of the present invention can be prepared by simple dissolution in water of the monohydroxamate and of the vanadium salt.
Examples of vanadium salts used to form the complexes used in the compositions of the present invention are, without being limited to, VOCl
2
(+4), VOSO
4
(+4), NaVO
3
(+5) and Na
3
VO
4
(+5).
Various HXM: vanadium salt stoichiometric molar ratios of the complexes are envisaged by the present invention, but 1:1 and 2 HXM: 1 vanadium salt molar ratios are preferred.
The complexes of formula I of the invention are prepared by mixing water solutions of the monohydroxamate and the vanadium salt, freezing and lyophilizing the solution, thus obtain
Fridkin Matityahu
Gershonov Eytan
Goldwasher Itzhak
Shechter Yoram
Aulakh Charanjit S.
Yeda Research and Development Co. Ltd.
LandOfFree
Vanadium complexes of monohydroxamates and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vanadium complexes of monohydroxamates and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vanadium complexes of monohydroxamates and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2852612